Results 61 to 70 of about 2,700 (156)

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

CONTINUOUS INFUSION OF PYRIDOSTIGMINE IN THE MANAGEMENT OF MYASTHENIC CRISIS: A CASE REPORT [PDF]

Acta Medica Iranica, 1998
Myasthenia crisis is the most dangerous complication of myasthenia gravis. We report one case in which a continuous infusion of pyridostigmine resulted in successful management of myasthenia exacerbation in a 50 year old myasthenic female following ...
M. Mojiahedzadeh., M. R. Ganjee., M. Rastegarpanah A.M. Sabzghabaee   +2 more
doaj   +2 more sources

Structural Lung Disease in Children and Adolescents With Severe Neurological Disorders

Pediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Background and Objective Children with severe neurological disorders are at risk of secondary respiratory morbidity due to impaired airway clearance and dysphagia, but systematic data on structural lung changes remain scarce. Methods We retrospectively analyzed all clinically indicated chest CT examinations at a tertiary care center (2015–2025)
Daniel A. F. Bernard, Cathrin Dahl, Luca Salhöfer, Anna Pauly, Mathis Steindor, Margarete Olivier, Ulrike Schara‐Schmidt, Matthias Welsner, Bernd Schweiger, Sebastian Zensen, Marcel A. Drews, Johannes Haubold, Michael Forsting, Lale Umutlu, Marcel Opitz, Florian Stehling   +15 more
wiley   +1 more source

Efgartigimod for patients with thymoma associated generalized myasthenia gravis during the perioperative period: a four-case report

Frontiers in Immunology
BackgroundThymectomy is one of the main treatments for thymoma associated myasthenia gravis, but there is a risk of acute exacerbation of myasthenia gravis symptoms during the perioperative period of thymoma.
Liuli Ren, Ling Wei, Song Jiang, Hongru Li, Anguo Chen, Juanjuan Zhang   +5 more
doaj   +1 more source

Myasthenia Crisis Management in the ICU: A Case Report

Jurnal Ilmiah Gema Perencana
This study focuses on analyzing the clinical course of myasthenic crisis in post-thymomectomy patients by examining the triggering factors, physiological responses, and the effectiveness of multidisciplinary interventions in stabilization and recovery ...
Dhita Natasha Dwiriyanti, Novita Anggraeni   +1 more
doaj   +1 more source

The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit

Arquivos de Neuro-Psiquiatria, 2013
Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission leading to generalized or localized muscle weakness due most frequently to the presence of autoantibodies against acetylcholine receptors in the postsynaptic motor end ...
Daniel Agustin Godoy, Leonardo Jardim Vaz de Mello, Luca Masotti, Mario Di Napoli   +3 more
doaj   +1 more source

Analysis of two cases of myasthenic crisis

Journal of Education, Health and Sport, 2019
Introduction: Myasthenia gravis is an autoimmune disease of the postsynaptic part of the neuromuscular junction. The disease is chronic, manifesting itself in the fatigue of various muscle groups, and the first manifestation of the disease often affects ...
Marcin Kulczyński, Klaudia Sapko, Michał Marciniec   +2 more
doaj   +3 more sources

Successful Treatment of Immune Checkpoint Inhibitor‐Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Immune checkpoint inhibitor (ICI) therapies are known to cause immune‐related adverse events (irAEs), including life‐threatening myocarditis, myositis, and myasthenia (MMM) overlap syndrome. Current literature lacks established therapeutic guidelines for effective management with steroid‐sparing agents.
Zeinab Alnahas, Sujata Sarkar, Oishi Roychoudhury, Ernest Algabre   +3 more
wiley   +1 more source

Severe Myasthenic Manifestation of Leptospirosis Associated with New Sequence Type of Leptospira interrogans

Emerging Infectious Diseases, 2019
We report the rapid development of a myasthenic crisis as the first-time manifestation of myasthenia gravis. The symptoms developed in the course of acute leptospirosis associated with a new sequence type of Leptospira interrogans.
Matthias Tomschik, Inga Koneczny, Anna-Margarita Schötta, Sebastian Scharer, Merima Smajlhodzic, Paloma Fernandes Rosenegger, Martin Blüthner, Romana Höftberger, Fritz Zimprich, Gerold Stanek, Mateusz Markowicz   +10 more
doaj   +1 more source

Myasthenic Crisis in Eclampsia: A Case Report

Thai Journal of Obstetrics and Gynaecology, 2009
Myasthenia gravis (MG) with eclampsia is a high risk condition. The use of magnesium sulfate to prevent seizure is contraindication because this may worsen MG and may develop myasthenic crisis.
Chanvitya Punthumapol
doaj